Julie Iwashita joined Pipeline Therapeutics in October 2020 as Vice President, Clinical Operations. She brings more than 30 years of experience leading clinical development programs through successful submissions and marketing approvals in various therapeutic areas including CNS, cardiorenal, infectious disease, metabolic disorders, and oncology. She has served as a clinical consultant for multiple private and public biotech companies exploring neurological disorders including age-related macular degeneration, spinal cord injury, and migraine headaches. Previously, she served as Vice President, Clinical Operations at Cirius Therapeutics. Prior to Cirius, she was Executive Director, Clinical Operations at Kodiak Sciences Inc., Laguna Pharmaceuticals, and Sorbent Therapeutics, and was previously Senior Director of Clinical Operations at MAP Pharmaceuticals, Proteolix (through acquisition by Onyx Pharmaceuticals), and Affymax. She has also led clinical programs at Aviron (through acquisition by MedImmune), Amgen, and Syntex. Julie holds a bachelor’s degree in human biology from Stanford University.